A mid-stage trial of two experimental skin rash treatments developed by Anacor Pharmaceuticals Inc. met their goals, the Palo Alto company said.
The drugs, known as AN-2728 and AN-2898, are designed to treat mild to moderate atopic dermatitis, a chronic rash that involves inflammation and itching. It affects about 40 million people in seven major countries, the company (NASDAQ: ANAC) said, including about 20 percent of children in the United States.
No comments:
Post a Comment